Centrus Energy funds nuclear fuel expansion with shares, pre-funded warrants and common warrants

Centrus Energy Corp. (NYSE: LEU) has priced an underwritten public offering expected to generate approximately $500 million of gross proceeds before fees, combining 500,000 Class A common shares with pre-funded warrants covering another 2,005,513 shares and common warrants that could eventually result in as many as 6,992,382 additional shares. The stock and accompanying warrants were priced at $199.64 per share package, while pre-funded warrant packages were priced at $199.54 with a $0.10 exercise price. Centrus said proceeds could support working capital, technology development, capital expenditure, debt reduction, acquisitions and other corporate purposes. The financing is notable because the nuclear-fuel company already held approximately $1.87 billion of cash at June 30, suggesting management is building capital capacity ahead of an unusually large enrichment expansion rather than solving an immediate liquidity problem.

The offering arrives as Centrus attempts to convert a strengthened nuclear-fuel market into new United States enrichment capacity. Second-quarter revenue increased to $176.1 million from $154.5 million a year earlier, while the company reported $4.5 billion of total backlog and approximately $3.0 billion of contingent low-enriched uranium and high-assay low-enriched uranium sales commitments. Capital expenditure reached $94.8 million during the first half compared with only $5.7 million a year earlier, providing direct evidence that the business has already entered a materially more capital-intensive stage.

How much near-term dilution comes from the $500 million Centrus financing before the larger warrants are considered?

Centrus is initially selling 500,000 common shares and pre-funded warrants representing another 2,005,513 shares. Together, those instruments represent approximately 2.51 million share equivalents before considering the common warrants. Centrus had roughly 19.95 million Class A and Class B shares outstanding at June 30, meaning the initial equity-equivalent issuance is approximately 12.6% of that pre-offering common-share base on a simple calculation.

The pre-funded warrants carry only a $0.10 exercise price, making their economic characteristics much closer to shares than ordinary warrants with a materially higher strike. Investors should therefore incorporate them when considering the financing’s likely effect on future share count even though they are technically warrants until exercised.

The larger optional dilution sits in the 6.99 million common warrants. Centrus has divided those warrants into four series with exercise prices of $226.8625, $272.2350, $317.6075 and $362.9800. Each series has an aggregate exercise value of approximately $500 million, implying that full exercise across all four could potentially supply roughly another $2 billion of gross capital over time if Centrus’ share price rises sufficiently and the warrants remain outstanding.

That future capital is not guaranteed. Warrants above the market price may expire without exercise, so investors should not count the potential $2 billion as funded cash today. What the structure gives Centrus is a staged financing mechanism that can bring in substantially more equity capital if the company’s valuation appreciates alongside its enrichment expansion.

Why would Centrus need more equity when cash already exceeds long-term debt?

Centrus reported $1.8685 billion of cash and equivalents at June 30 against approximately $1.1775 billion of long-term debt. The $500 million gross offering therefore equals roughly 27% of the June cash balance rather than representing a rescue financing for a heavily cash-constrained company.

The balance-sheet logic becomes clearer when capital expenditure is examined. First-half capex increased more than sixteenfold to $94.8 million as Centrus advanced centrifuge manufacturing and enrichment-expansion work in Piketon, Ohio, and Oak Ridge, Tennessee. Management expects its first new centrifuge from the current manufacturing programme to be completed in Oak Ridge before the end of 2026.

Building uranium enrichment capacity is fundamentally different from expanding a software business. Specialized centrifuge production, cascade installation, supporting infrastructure, security, testing and regulatory requirements consume capital before commercial output can begin.

Centrus can therefore reasonably prefer excess financing capacity while customer commitments and government programmes are expanding. The economic risk moves from whether it can finance construction toward whether the new plants and centrifuges are completed on schedule and backed by durable demand.

How much of Centrus’ $4.5 billion backlog is already firm commercial revenue?

The headline backlog needs qualification. Centrus reported approximately $4.5 billion across its Low-Enriched Uranium and Technical Solutions segments at June 30, but around $3.0 billion represented contingent LEU and HALEU enrichment commitments. Approximately $2.4 billion of those contingent commitments were under definitive agreements supporting potential new production capacity.

Contingent commitments can depend on operating milestones, construction decisions or other conditions. They therefore provide stronger demand visibility than informal customer discussions but should not be treated identically to unconditional contracted sales ready for near-term recognition.

Technical Solutions backlog also contained approximately $0.8 billion related to the existing Department of Energy HALEU operation contract. Centrus disclosed that the proposed fiscal 2027 DOE budget did not contain additional funding for further operation of that cascade and that DOE did not currently intend to exercise additional options under that contract.

This creates an important transition inside Centrus. The company is moving from a business heavily influenced by government demonstration work toward an enrichment platform increasingly supported by commercial LEU and HALEU demand. The $500 million financing provides capital to make that transition, but backlog conversion will show whether commercial customers ultimately justify the investment.

Why did Centrus Energy shares fall sharply after the offering was priced?

Centrus shares closed at $165.87 on September 10, down 8.61% from $181.49 the previous day. The offering terms were announced after the September 9 regular-session close, so investors had their first full trading day to digest the financing on September 10.

The decline is directionally consistent with concern about equity dilution, but it should not automatically be attributed entirely to the offering. Centrus is a volatile nuclear-fuel stock whose valuation can respond sharply to uranium-market expectations, government policy and broader risk appetite.

One detail is particularly unusual: the $199.64 combined offering price sat above the September 9 common-stock closing price. Investors in the offering were receiving common-warrant exposure alongside their shares or pre-funded warrants, however, making a simple comparison between the package price and the standalone share price incomplete.

The more important valuation question is what Centrus does with the proceeds. Dilution can create value if the capital funds enrichment assets capable of generating attractive returns from long-duration customer demand. It destroys value if the company issues shares faster than incremental operating earnings materialize.

What would prove that the $500 million Centrus financing was strategically well timed?

The first evidence will be progress at Piketon and Oak Ridge. New centrifuge manufacturing needs to transition into installed, qualified production capacity rather than remain a capital programme measured primarily by spending.

Customer prepayments would provide another powerful signal. Centrus said its first large-scale commercial HALEU supply agreement potentially includes customer prepayments, which could reduce the amount of corporate capital required as production expands.

Backlog composition should also improve. Investors will want contingent enrichment commitments to become firm orders as operating and construction milestones are achieved.

Centrus has used a strong nuclear-fuel market to create one of the more unusual balance sheets in the sector: substantial cash, large contingent demand and rapidly rising capital expenditure. The $500 million offering increases the financial cushion even further. From here, physical enrichment capacity and firm revenue conversion matter more than another financing headline.

Key takeaways on Centrus Energy’s $500 million offering

• Centrus Energy has priced an offering expected to generate approximately $500 million of gross proceeds.
• The transaction includes 500,000 common shares and pre-funded warrants covering about 2.01 million shares.
• Initial equity-equivalent issuance is approximately 2.51 million shares.
• That represents roughly 12.6% of Centrus’ June common-share count on a simple comparison.
• Another 6.99 million common warrants could create additional future dilution.
• The four warrant series could generate roughly $2 billion collectively if fully exercised under their stated terms.
• Centrus held approximately $1.87 billion of cash at June 30.
• First-half capital expenditure increased to $94.8 million from $5.7 million a year earlier.
• Total backlog stood at approximately $4.5 billion, including substantial contingent enrichment commitments.
• LEU shares fell 8.61% on September 10 after the offering terms were announced.